Phaseline

Targets › APOE

APOE (Apolipoprotein E): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Nov 2028.

APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids. APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance. (UniProt, P02649)

Open in Phaseline: the race on APOE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Lexeo TherapeuticsLX1001 (AAVrh.10hAPOE2)
Gene therapy delivering human APOE2 via adeno-associated virus serotype rhesus 10
APOEPhase 1Alzheimer DiseaseNov 2028

Conditions

Alzheimer Disease (1)

Modalities

protein or peptide (1)

Companies

Lexeo Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.